<SEC-DOCUMENT>0001477932-15-002056.txt : 20150331
<SEC-HEADER>0001477932-15-002056.hdr.sgml : 20150331
<ACCEPTANCE-DATETIME>20150331123625
ACCESSION NUMBER:		0001477932-15-002056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150331
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150331
DATE AS OF CHANGE:		20150331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		15737697

	BUSINESS ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577
		BUSINESS PHONE:		800-537-2790

	MAIL ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bvx_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head></head>
<body style="font: 10pt TIMES NEW ROMAN; text-align: justify; margin: 0px 7% 0px 7%;">
<p style="margin: 0px;">&#160;</p>
<div style="border-bottom: #000000 4px solid; margin: 0px; width: 100%; font-size: 1px;"></div>
<div style="border-bottom: #000000 1px solid; margin-top: 2px; width: 100%; font-size: 1pt;"></div>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><font style="font-size: 12pt;"><b>UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="text-align: center; margin: 0px;"><font style="font-size: 12pt;"><b>Washington</b><b>, DC 20549</b></font></p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><font style="font-size: 18pt;"><b>FORM 8-K</b></font></p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><b>CURRENT REPORT PURSUANT<br /></b><b>TO SECTION 13 OR 15(D) OF THE<br /></b><b>SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="text-align: center; margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><b>March </b><b>31</b><b>, 2015</b></p>
<p style="text-align: center; margin: 0px;">Date of Report (Date of earliest event reported)</p>
<p style="margin: 0px;">&#160;</p>
<table id="tableid0" style="width: 45%; text-align: left; font: 10pt TIMES NEW ROMAN; margin: auto;" cellspacing="0" cellpadding="0" align="center" border="0">

<tr height="15">
<td style="border-bottom: black 1px solid;">
<p style="text-align: center; margin: 0px; font: 10pt TIMES NEW ROMAN;"><font style="font-size: 18pt;"><b>BOVIE MEDICAL CORPORATION</b></font></p>
</td>
</tr>
<tr height="15">
<td>
<p style="text-align: center; margin: 0px; font: 10pt TIMES NEW ROMAN;">(Exact name of registrant as specified in its Charter)</p>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<table id="tableid1" style="width: 85%; text-align: justify; font: 10pt TIMES NEW ROMAN; margin: auto;" cellspacing="0" cellpadding="0" align="center" border="0">

<tr height="15">
<td style="border-bottom: black 1px solid;" valign="top" width="30%">
<p style="text-align: center; margin: 0px;"><b>Delaware</b></p>
</td>
<td valign="top" width="5%">&#160;</td>
<td style="border-bottom: black 1px solid;" valign="top" width="30%">
<p style="text-align: center; margin: 0px;"><b>012183</b></p>
</td>
<td valign="top" width="5%">&#160;</td>
<td style="border-bottom: black 1px solid;" valign="top" width="30%">
<p style="text-align: center; margin: 0px;"><b>11-2644611</b></p>
</td>
</tr>
<tr height="15">
<td style="text-align: right;" valign="top">
<p style="text-align: center; margin: 0px;">(State or other jurisdiction of incorporation)</p>
</td>
<td style="text-align: right;" valign="top">&#160;</td>
<td style="text-align: right;" valign="top">
<p style="text-align: center; margin: 0px;">(Commission File Number)</p>
</td>
<td style="text-align: right;" valign="top">&#160;</td>
<td style="text-align: right;" valign="top">
<p style="text-align: center; margin: 0px;">(IRS Employer Identification No.)</p>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><b>4 Manhattanville Road, Suite 106<br /></b><u style="line-height: 1;"><b>Purchase, New York 10577</b></u></p>
<p style="text-align: center; margin: 0px;">(Address of principal executive offices) (Zip Code)</p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><u style="line-height: 1;"><b>(914) 468-4009</b></u></p>
<p style="text-align: center; margin: 0px;">Registrant's telephone number, including area code</p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;">&#160;______________________________________________</p>
<p style="text-align: center; margin: 0px;">(Former name or former address, if changed since last report)</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin: 0px;">&#160;</p>
<table id="tableid2" style="width: 100%; text-align: justify; font: 10pt TIMES NEW ROMAN; margin: auto;" cellspacing="0" cellpadding="0" border="0">

<tr height="15">
<td valign="top" width="4%">
<p style="margin: 0px;"><font face="Wingdings"><font face="Wingdings"><font face="Wingdings">&#168;</font></font></font></p>
</td>
<td valign="top">
<p style="margin: 0px;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td>
</tr>
<tr height="15">
<td valign="top">&#160;</td>
<td valign="top">&#160;</td>
</tr>
<tr height="15">
<td valign="top">
<p style="margin: 0px;"><font face="Wingdings"><font face="Wingdings"><font face="Wingdings">&#168;</font></font></font></p>
</td>
<td valign="top">
<p style="margin: 0px;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td>
</tr>
<tr height="15">
<td valign="top">&#160;</td>
<td valign="top">&#160;</td>
</tr>
<tr height="15">
<td valign="top">
<p style="margin: 0px;"><font face="Wingdings"><font face="Wingdings"><font face="Wingdings">&#168;</font></font></font></p>
</td>
<td valign="top">
<p style="margin: 0px;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td>
</tr>
<tr height="15">
<td valign="top">&#160;</td>
<td valign="top">&#160;</td>
</tr>
<tr height="15">
<td valign="top">
<p style="margin: 0px;"><font face="Wingdings"><font face="Wingdings"><font face="Wingdings">&#168;</font></font></font></p>
</td>
<td valign="top">
<p style="margin: 0px;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<div style="border-bottom: #000000 1px solid; margin: 0px; width: 100%; font-size: 1pt;"></div>
<div style="border-bottom: #000000 4px solid; page-break-after: always; margin-top: 2px; width: 100%; font-size: 1pt;"></div>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>Item 8.01</b> <b>Other Items </b></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">On March 31, 2015, Bovie Medical Corporation (the &#8220;Company&#8221;) issued a press release announcing that Craig-Hallum Capital Group LLC, the underwriter of the Company&#8217;s previously announced public offering registered on the Company&#8217;s Registration Statement on Form S-3 (File No. 333-200986), has exercised a portion of its over-allotment option to purchase an additional 418,749 shares of common stock at an aggregate price of $2.50 per share. After closing of the over-allotment, the total number of shares sold by the Company in the offering is 5,218,749. A copy of this press release is filed as Exhibit&#160;99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>Item 9.01 Financial Statements and Exhibits</b></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">(d)</p>
<p style="margin: 0px;">&#160;</p>
<table id="tableid3" style="width: 100%; text-align: justify; font: 10pt TIMES NEW ROMAN; margin: auto;" cellspacing="0" cellpadding="0" border="0">

<tr height="15">
<td style="border-bottom: black 1pt solid;" valign="top" width="8%">
<p style="margin: 0px;"><strong>Exhibit No.</strong></p>
</td>
<td valign="top" width="2%">&#160;</td>
<td style="border-bottom: black 1pt solid;" valign="top" width="90%">
<p style="margin: 0px;"><strong>Description</strong></p>
</td>
</tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="margin: 0px;">99.1</p>
</td>
<td valign="top">&#160;</td>
<td valign="top">
<p style="margin: 0px;">Press Release dated March 31, 2015</p>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<table id="tableid4" style="width: 100%; font: 10pt TIMES NEW ROMAN;" cellspacing="0" cellpadding="0" border="0">

<tr>
<td>&#160;</td>
</tr>
<tr>
<td>
<div class="rcpn" align="center"><font size="2" face="Times New Roman, Times, serif">2</font></div>
<div class="hpbhr" style="width: 100%; font-size: 1pt;"></div>
<hr color="#000000" size="1" width="100%" noshade="noshade" />
<div style="line-height: 0px; page-break-after: always; width: 100%;"></div>
</td>
</tr>
<tr>
<td>
<div class="hdr" style="width: 100%; font-size: 1pt;"></div>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;" align="center"><strong>SIGNATURES</strong></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
<table id="tableid5" style="width: 100%; text-align: justify; font: 10pt TIMES NEW ROMAN; margin: auto;" cellspacing="0" cellpadding="0" border="0">

<tr style="background-color: white;" height="15">
<td valign="top"></td>
<td valign="top" colspan="3">
<p style="margin: 0px;"><strong>BOVIE MEDICAL CORPORATION</strong></p>
</td>
</tr>
<tr style="background-color: white;" height="15">
<td valign="top" width="50%">&#160;</td>
<td valign="top" width="3%">&#160;</td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="12%"></td>
</tr>
<tr style="background-color: white;" height="15">
<td valign="top">Date: March 31, 2015</td>
<td valign="top">By:</td>
<td style="border-bottom: black 1pt solid;" valign="top">
<p style="margin: 0px;"><em>/s/ Robert L. Gershon</em></p>
</td>
<td valign="top">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr style="background-color: white;" height="15">
<td valign="top">&#160;</td>
<td valign="top">&#160;</td>
<td valign="top">
<p style="margin: 0px;">&#160;Robert L. Gershon</p>
</td>
<td valign="top">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr style="background-color: white;" height="15">
<td valign="top">&#160;</td>
<td valign="top">&#160;</td>
<td valign="top">
<p style="margin: 0px;">&#160;Chief Executive Officer</p>
</td>
<td valign="top">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;">3</p>
<hr color="#000000" size="1" width="100%" noshade="noshade" />
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bvx_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head></head>
<body style="font: 10pt TIMES NEW ROMAN; text-align: justify; margin: 0px 7% 0px 7%;">
<p style="text-align: right; margin: 0px;"><strong>EXHIBIT 99.1</strong>&#160;</p>
<p style="text-align: center; margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;"><img src="bvx_ex991001.jpg" ></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;" align="center"><b>BOVIE MEDICAL CORPORATION ANNOUNCES CLOSING OF OVER-ALLOTMENT OPTION</b></p>
<p style="margin: 0px;" align="center"></p>
<p style="text-align: center; margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>CLEARWATER, FL &#8212; March 31, 2015 &#8211; </b>Bovie Medical Corporation (&#8220;Bovie&#8221; or the &#8220;Company&#8221;) (NYSE: BVX), a maker of medical devices and supplies and the developer of J-Plasma<sup>&#174;</sup>, a patented new surgical product, announced today that it has closed the sale of an additional 418,749 shares of its common stock pursuant to the over-allotment option of the underwriter in connection with its recent public offering of common stock. After closing of the over-allotment, the total number of shares sold by Bovie in the offering is 5,218,749. The total net proceeds of the offering, after deducting underwriting discounts, commissions and estimated offering expenses, are approximately $11.6 million.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Craig-Hallum Capital Group LLC acted as sole managing underwriter for the offering.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">The shares are being offered pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus. The prospectus and prospectus supplement related to the offering have been filed with the SEC and are available on the SEC&#8217;s website located at http://www.sec.gov and may also be obtained from Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, telephone 612-334-6300, email: prospectus@chlm.com.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>About Bovie Medical Corporation</b></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma&#174;, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma&#174; utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company&#8217;s own well-respected brands (Bovie&#174;, Aaron&#174;, IDS&#8482; and ICON&#8482;) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company&#8217;s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation&#8217;s website&#160;www.boviemed.com.</p>
<p style="margin: 0px;">&#160;</p>
<table style="width: 100%; font: 10pt TIMES NEW ROMAN;" id="tableid0" border="0" cellspacing="0" cellpadding="0">

<tr>
<td>&#160;</td>
</tr>
<tr>
<td>
<div class="rcpn" align="center"><font size="2" face="Times New Roman, Times, serif">1</font></div>
<div style="width: 100%; font-size: 1pt;" class="hpbhr"></div>
<hr color="#000000" size="1" width="100%" noshade="noshade" >
<div style="line-height: 0px; page-break-after: always; width: 100%;"></div>
</td>
</tr>
<tr>
<td>
<div style="width: 100%; font-size: 1pt;" class="hdr"></div>
</td>
</tr>

</table>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>Cautionary Statement on Forward-Looking Statements</b></p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company&#8217;s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company&#8217;s filings with the Securities and Exchange Commission including the Company&#8217;s Reports on Forms 10-K and 10-Qs for the year ended December&#160;31, 2014 and the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;"><b>Investor Relations Contact</b></p>
<p style="margin: 0px;">Hugh Collins</p>
<p style="margin: 0px;">MBS Value Partners</p>
<p style="margin: 0px;">(212) 223-4632</p>
<p style="margin: 0px;">investor.relations@boviemed.com</p>
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
<p style="text-align: center; margin: 0px;">2</p>
<hr color="#000000" size="1" width="100%" noshade="noshade" >
<p style="margin: 0px;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>bvx_ex991001.jpg
<TEXT>
begin 644 bvx_ex991001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!.`($#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_*.E%&:`
M&@C'\Z0''XTR:1;="SL$4<Y)P!7@?QV_X*,_#SX)RS6<5\?$>L1Y'V/3B)-C
M>CR?<7\\^U=F!R[$XRI[+"TW.7DOZL>/F^?9?E=+VV/JQIQ\W^2W9[^>!S^=
M<UXZ^+OAGX969GU[7=,TF/&0;FX5,_0$Y/X5^=OQ$_X*(_%;]H#66T?PG;SZ
M-'<';'::3"US>N/]J3&1]0!]:N?#K_@F#\3/B_>KJGB[4(M#2<[GDOYFOKUL
M_P"SG`/U;\*^UI\$TL+!5,YQ$:2_E6LOZ^\_*JWBQB<PJ.APQ@I5VOMR]V*_
MKU1])^-/^"K'PM\+SO%8SZKKS(<!K&T/EG_@3E161X4_X*Z_#S6=5BM]0T[7
M](AE8*;F:W5XDR>K;6)`]\&K7P[_`."3GPW\**LFMR:KXCG7!;[3<>5$3_N1
MX_G7RS_P4(\'?#GP'\3]/\/?#[38[>^LT9=4CM&9XVD8CRXQDG]YUR!Z@5Z>
M491PSF&(^I895).S?.[)*W5_\,>!Q'Q+QWD^$6:8Z5&*NDJ:3<G=[+O\F?J!
MH^K6NOZ7;WME-%<6MS&LL4J-N1T89#`]P15P9_,5YG^R#\/]0^%W[.'A/1-6
M9C?V5B@F5CDQELML_P"`@X_"O2]P'%?F6+I1I5YTZ<N9)M)]TGN?OF5XFIB,
M'2KUH\LI13:[-J[0#)&2*5OS-&W`X/%>=?';]I_P=^SEI]M<>*M5%F;Q]D,,
M<9EFDQU(1<G:.YZ5&'P]2M-4Z47*3V2U9KC,;A\)2=?$S48K=MV1V'C/Q+%X
M,\*:CJ\Z2/!IMM)<NL:[F944L<#UXKP3]A/XS?$?]H2\\1^*_$\:V'A&\=4T
M*Q:V$;)@G<P;:'88P"6)!.<8%=Y\0_VO?`/PVMO#CZIJXV>+O+_LY(X6E>='
MQM<J!D+\PY/K77?$;XE:!\&_!-QK6MWEOIFEV4>YG;CZ*JCDL>P%>I1IU*=!
MT'0O.HTHMK71ZJ*[MZ-GSN*KT,1C88N&+Y:5!-RBFDFVM')WV2U2.E'4?K2'
MYCCK^%?G?\6_^"N?BC5_$CIX+TK3]-TN!_DDU!#+/<#U900$!].3[U]F_LN?
M&J3X^?!+0?%%S:#3[K4XBTL`.5#JQ4E<\E21D?6NK->%LQR[#0Q.*A:,G;=7
M3WU1Q<.^(>2YWCJF`P%1RG35[V:35[:/KJ>B[?\`9_6BG45\X?<D97:"3CWK
MQ#]IG]O#P9^S?%)9RS'6?$6W,>F6;!G4]C(W2,?7GVKQ;_@HE^WMK7P\\67G
MP_\`")?3]0MXT&H:D5_>1^8BNL<`]2K+ENQ.!R*\I_9E_P"":_BOXWW$>N^,
M9KSP]HMVWG.)LMJ%_GDMAL[`?[S<^U?H&3<+86GAHYGG53DI/6,5\4O^`_+\
M#\6XH\0\QKXZ>1<+4?:5T[2FU[L'U\KK[CD?BM^UQ\4?VO/$?]BV1ODMKML0
MZ)HJMAA_TT8?,WN6(7VKUW]GG_@DG?:I%%J/Q#U`:;;_`'_[+L'!D/M)+T'T
M7/UK[(^#?[//A+X!Z"NG^&M'MK%2/WLVW=-.?5W/S,?K7E__``41_:C'[/\`
M\(WT_39U3Q)XB5K>SP?FMTQB2?\`X"#@>Y%>BN+*^*J1RKA^DJ,).UTO>?FW
MTTU>[/#EX=8;+\-//^,:[Q%2*YK-OE3Z)+KKHEL<%\(/C5I'AS]J^R^%_P`*
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MG>O_`*C^(W,Y;^/N`>G4\UW_`.QU_P`$X=(^"9M?$7BS[/K7B>,"2*(+FUTT
M_P"P#]YQ_>/X`5Y9^W9\=];_`&F?C-:_![P0QELDN1;WS1MA;N<<LKD?\LHA
MRWJ1[5ZF%JX><7D^2OEA:]6J]VEO;LNQ\_CZ&,IRCQ+Q2N>LVEA\.ME)[7[O
MJSV2#_@JG\,I_B`FBH^J_8Y)Q;KJOV;%IN)QNSG=LS_%BK?_``4;_:7O_@3\
M%+4^'+X6>N>(+@0VMR@#M#&!ODD7.1G&`/\`>KX]_;G_`&;O#W[-5OX,\/Z2
MTMWK]U:2S:G<,YW71+*J';T4;MP`'8=ZM?MP>,CK/Q8\$>&M7G9;;PII-C!J
M!Y;9)($:8D=R(P*ZL'PEEM7%87$8+FE3ESMJ6MU#9V\WT//S'Q)SRA@<?@<S
M<858N$8RCIR\^K5^\5?4^VM&^/C?`W]C[1/%?CR_:YU0:9%)*2H66\G==RQJ
M!QN.0/P)KXK\!:'J7[9/Q-U[XG_$6=[;P3X;!GNSDB,(GS)9Q?IN(Y.?5JG\
M=>*/$/\`P48_:)T[PUH`FL_"ND`);@KA+2W7"O<R#^^P&%'T'K72_P#!0+Q9
MI_PW\.^'?@AX(A9+2P6*6_CAYDN96/[J-B/O,S'>WN5K7*\K^I5?J\$EB:UY
M2:_Y=4]WZ-K0YL_X@GFV&^N56W@L-RQ@G_R_JVLF^Z3U96_9<MO^&GOVE-6^
M)OB98[+PGX(C%Q!"^!!:+&#Y$('0!%!<^^*XK]H#]H@_ME?&U?[5UH>'/`>D
M,TENLA((A7[T@0??GDZ*O;(]#7<_M56W_#)_[)GA;X8V;^7J_B?-_KTB'!E`
MP74GT+%5^B5QGP=_8!USQ)HR^)O'=Y!X)\&P1"YFN+F11=2Q=?E7I'D=VYYX
M%>S@G@$I9KB)<L5>%%;NRT<HK6[;OT/ELT6;-0X?P<'.;M5Q#VCS2U49/1*,
M59/5:W,G0/!-E^TUXV5=-L+;P7\,_"$6+N_D`#0P`Y:263_EI<2XX';(].?K
MWP#\))?%OCWPIXE\!W]M>^`[-;=+&6"[:-(8(F4/&4ZY^1QC'S&0[NE?,VL:
ME=?M9>,-+^$_PJTYM&\!:7())9"I!N`#\UW<'J?]E3R3C\/T5^#GPKTSX*_#
M;2?#.D*4L=*@$2EOO2MU9V]V.2?K7RG&&9SHTJ<6[2::4'K:+^U)[\S?W(_0
M_##AZEB<16G&*E"+3=5:<TT_A@MN2/XLZC8WJ/SHJ3>**_+><_HSV2.4\0_!
M+PGXJ\8VOB'4?#^E7NMV8`@O)K97FCQTPQ].WI74!55<```42$1(3UP,U\#_
M`+3G_!5K5#KVH^'_``%8QV0M9GM'U.[3?*[J2I\J+MR#@MD^U>WE&48[-ZBH
M8?7E6[>B7]=$?)\2<2Y1PU1>,Q2Y7-[1C[TG\MWZGV5\6OC?X:^"?AR74_$6
MK6NGP(I*K(X\R8C^%%ZL3[5^3/[1WQTO_P!HKXM:CXDOM\<=PWD6-J3G[-;J
M3L0#U[G'4DUS?C7QCK?Q`\0R7^OW^HZMJ3MAI+MV>0'^Z`?N_0`5^C/[!_[#
MFD?"3P+8>(/$>FV]YXNU%!.YN8P_]GJ>5B0'@,!C<>N<^E?J>&R_`\'4/KN)
M?M:\]$EHO.WEW9_/6-SK-O$S&_V9@5[##4W>3>K\K^?9'QAI?P)^,O[3MY9W
M#Z/XAU6.&,16T^I'[/;0Q@8PF_``QZ#FO7_AY^PQ\>?@;H^H:CX=U[0M&N+B
M,/<0QS!Y)=@)"[VC('?OBOT*8Q6,>[Y(HU&2<8`KX;_;U_X*&Q7UM>^!O`-Q
M]I>?-MJ.JP?,!GY6AAQ]YCT+#UP,FO+P7%F:YS66"P=&$:75<MXI7^U?3\#W
M\X\.>'^&,*\RS+%5)XBWNM2M)RM9**6IY-X1_P""GGQ1\+Z)?Z=J%QIVN/*C
MQ0W%Q"$EM7Y&X%,!\>A'XUZ]_P`$L?AA;^'O"OB7XJ^('`DN#+#;W,Y^Y$F7
MGER?[S=_]DU\Q_&']E3Q%\#/A7X9\1:ZIM)?$DLD:V)3Y[-0H9/,/]YAD[>V
M*Z_QA^UO>^+?V<_"OPE\':5>V@>".UU%D&9;^0M_JH@O.UF.23R>G3-?5YME
M&%Q."Y,FC&,:LK5)QT2C&_-^/;1GYWP_Q%CL#FGMN)9RG4H0YJ,)7<G*=N7\
M'?78Z#X?75S^W-^W1-XCO%/_``CVBR?;F#_<AM(#^Y0^[L,GZMZ5XE\5_$EU
M\9?CCKE_9Q27ESKNJR)9PQC<TH+[(D'X!17Z,_LC_L=_\*0_9XU#2;ETC\3^
M*+9VU"X09\EW0JB*?[J`_B<FO//V$?\`@G?J?P5\?W/B;QLMA-?:<S0Z3#"_
MFH`>#<$XX8CA1U&37B8/C#+L)4Q%6FU:E!0IQ_F[OYNU_)'U.8>&><YC1PE"
MM%\V(G*K6E_+>UD_17LN[L=W^S]\&])_8._9AU77-7\M]8%H;_5K@=7D"_+"
MI_N@D*/4DGO7SY_P3T^$.H?M*?M":O\`%'Q(AFM-.O'N(RXRLUX_*@>T2D?C
MMK[P^)_PYTGXM>!]1\/:Y#]ITK5(_*GCWE"1D$8(Y!!`/X5S7AK_`(5]^RI\
M/[;18-0TGP]I%BI*+<72JS$G+,Q8Y9B>IKX;#<15G0Q+BG+$5W9R[1ZI===O
M2Q^M8[@C#0QF"A4G&&"PL;J+=N:?1N^GGZGQU_P5M^&^NQ?%S0O$MO8W=QI#
M6"VBSPQ&18)DD9MK``XSN!&>N#6#X1^#?QM_;SNM/_X2:[O-(\)VFW;+<V_V
M:$@<;HX!@R/_`+3<#UKZ7^(?_!4+X2^%U>"#4+CQ%..%CL+4RAC_`+S87]:Y
M"W_X*"_$3XG8B^'_`,'M9N8F/R7>H/Y4)'8]`/\`QZOI<'F.;TLOIT%A8QE3
M349SLK)]4I6U\]3X3-<CX;K9U7QCQTYPK-.5*DF^9KHW&^GD?0'[/?[.'AK]
MF[P9'I&@6H#/A[FZE^:>[D_O.W\AT':O0B1CIUKY>\-^&_VFOB-J=O)K.N>$
M_`^G&16EBL[;[7<A,Y(&[*Y[<FOIV%#%&JNV]E`!8CJ?6OSO-J<XU>>M552<
MM6TV_O=K?<?MO#6(HSPWL<+AI4*<+**DE&Z\E>_WDV1ZBBBBO+N?3##R.1]:
M\J^-6B^`_@GX4UWQ[?>'=$2]LH6N'N!:1B:>3HH#8SN9B!GKS7JN>WZU\!?\
M%:?CXVL>(],^'>G.QBM-E]J*ISYDC<0Q8'H/FQZE:^BX6RVKC\PAAJ;:B]9-
M.WNK<^$\1,[PV4Y-4QM:*E-:032?O/16O]YYI^P[X''[3'[7QUGQ!);,MM+)
MKES`Y`^T2[_D15[A6()]E%?H?\8/VA?"'P#\/F]\2:Q:V"*N8X-VZ>8^B(/F
M;\!7Y8Z1X#^*/P"\<VUQI^A^)-'UV2W(@EM[)IBT<@Y`(#+R/Q!%>L_"7_@G
M5\2_VA/$2ZWXXN[W1+2=MTUSJ,AGU&<>BH3\G_`L8]*_3^*LFP&*Q,,9B\7%
M4(Q2C&.LM.B]>^I^`^'G$^;Y=@*F79;E\IXNI)RE.2:CKLWMMVN._:$_;D\<
M?M@>(AX0\":;J5CI-ZQC6UM>;V_7IF5AQ''ZC./4U[U^Q7_P3?L?@[+:^)?&
M(MM4\3)A[>V7Y[;33ZC^_)_M=!V]:]H^"?[._@O]F+PN\&B65O980-=7UPP,
M]P1_%)(>OTX`]*XGXP?\%)/AG\*/-MX=5;Q!J,?'V;3%\\!O0OP@_.ODL1F]
M?%TO[+X?H.%+K97E+_$^GWGZ-@N&<'EU=9]QIBXU,1O%2:48>48]6O0]+^.7
MP(\._M">")-`\26CSV;.)(VB<I+"XZ.C#H>OYUYS\$_V&/AM^S)K3Z_;"6ZU
M&!2$O-3N!(;93UV<!5X[]:^8?B%_P5;\??$/4/[.\&:%;:0TYVQ`(;Z\?/HH
M&T'\#5#1/V-OCU^U).MWXNU2^TVRE^;_`(F]TV0/]FV3@?CBM\/PYF&#PKI9
MABUAZ4MX\UV_^W5_F<N.XWR;,\?'$Y-ETL77CHI\MDNVK70^M?BI_P`%$/A?
M\*R\,FOQZO>QY!MM-7[2V?0D?*/SKP/Q9_P5NU_QIJ)L/A_X&FN9W.V-K@M/
M*?3]U$./Q:O0/A-_P24\!^#A'-XBN;_Q1<+@M'(WD6V?]Q.2/J:^CO!/PI\.
M?#C3EM-"T73=+@48V6T"IGZD#G\:\N6)X=P6E&G*O+O)\L?N6OWGT%/+^-\V
M][%UX82F_LP7-+[WHOD?$UEX`_:G_:4</JFK2>#]-FZH76T(4_[$>9#^)%=I
MX$_X)#Z$UTMYXT\4:SXENC\TB(WDQD^A8EG/YBOL9$VG@"E*\>IKCK\7XUKD
MPJC1CVA%+\=SU<'X8Y6I>TS&4\3/O4DVONT7WW/-?AO^R+\.OA0B'1/"NDVT
ML8&)G@$LWUWOEL_C7HT=M';H`B*H[8&*D)XZ"EY*U\Y7Q=:O+GK3<GYNY]S@
M\LPF$CR86E&"\DE^0HZ48YS116!WA1110`QUR"!UKY+\)_\`!/+4)_VP=3\?
M>*]3LM8TAKM]1LH`K"3SMP\M9%/&V,8Q@\D#BOK-FV@4`\BO0R_-,1@E/ZO*
MW.K/O;R['A9UPW@LU=&6-CS>RES172_FNHTVT>5S&F5''%>!?MT_MHQ_LJ^&
MK.VTZSBO_$>L!C:Q2L1#`BX!E?')&2``.IKW]OE'/.*P/$_PI\->.=7M+_6-
M`T?5+VR!%O<7=G'-+`#R0K,"5Y]#2RVOAZ6)C4Q<'."WC>U_F//<%C,1@9T,
MMJ*E4EHI6O;N[=S\RQ:?'7]NG4=[+K.H:9(W5LV.EQ_0<!O_`!XU[M\&/^"/
MMC9QQ7'CC7I;QA@FQTT>3"/8R'YC^`%?;%G:Q6D0CAC2)%X"JH4`?A5C`R:^
MJQW'F-</8X&,:%/M%:_?_D?G>4>#V60J+%YQ4EBJO5S;Y;_X;G$_"S]GWP;\
M%[$0>&_#^G:8`,-)'$#*_P#O.<L?Q-=IP%XP*"-O`XI<?+FOBJU>I5FZE63D
LWU;NS]6PF!P^%IJEAH*$5LDDE^`ZBBBLSJ"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
